Pfizer’s Next-Generation Breast Cancer Therapy Shows Promising Results

Pharmaceutical giant Pfizer is actively working to secure its future revenue streams as the patent expiration for its blockbuster drug Ibrance approaches. New clinical data for its prospective successor, atirmociclib, has generated positive momentum on Wall Street, with analysts upgrading their outlooks.

Wall Street Responds with Upgrades

The release of promising Phase 2 trial results triggered immediate action from financial institutions. HSBC upgraded Pfizer’s stock to a “Buy” rating, raising its price target from $29.00 to $32.00. This move reflects growing confidence in the company’s oncology pipeline strategy, a sentiment further evidenced by recent position increases from institutional investors like Morgan Stanley.

This optimism is visible in the stock’s performance. Closing yesterday at €23.82, the share price is now trading just 1.5% below its 52-week high. Since the start of the year, the equity has posted a solid gain of nearly eleven percent.

Should investors sell immediately? Or is it worth buying Pfizer?

Significant Clinical Milestone Achieved

The focal point of this renewed interest is the FOURLIGHT-1 study. In this trial involving 264 patients, the breast cancer treatment atirmociclib successfully met its primary endpoint. The data showed a 40% reduction in the risk of disease progression or death. Unlike older therapies in its class, this candidate is designed to selectively inhibit the CDK4 protein, which Pfizer states enhances both efficacy and tolerability. The rate of treatment discontinuation due to side effects was a manageable 6.4%.

Securing Post-Ibrance Revenue

The clinical success is critical for Pfizer’s long-term financial stability. Ibrance, currently a key revenue driver, already reported a 5% sales decline in 2025. Market researchers at RBC Capital Markets project that atirmociclib could eventually achieve peak annual sales of approximately $2.6 billion, helping to offset the impending loss of exclusivity for its predecessor in 2027.

Attention now turns to the ongoing Phase 3 trials, which are evaluating atirmociclib as a first-line treatment. These late-stage studies must confirm the initial positive findings before the drug’s targeted market launch in 2027. According to Morgan Stanley, final data from these crucial trials is expected by 2029 at the latest.